KROS
Keros Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Keros Therapeutics doses the first patient in a Phase 2 trial evaluating rinvatercept in Duchenne muscular dystrophySep 28, 2026
- Keros Therapeutics presents additional clinical data from its KER-065 program at the American Society of Bone and Mineral Research 2025 annual meetingSep 8, 2025
- Keros announces U.S. FDA orphan drug designation granted to KER-065 for treatment of Duchenne muscular dystrophyAug 21, 2025
- Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial of elriterceptJul 17, 2025